This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

High dose vitamin D in multiple sclerosis (MS)

Authoring team

A study investigated whether vitamin D reduce disease activity in patients with clinically isolated syndrome (CIS) typical for multiple sclerosis when given at a high dose as monotherapy (1):

  • randomised clinical trial including 303 patients treated with oral high-dose cholecalciferol or placebo
  • primary outcome measure of disease activity was defined as occurrence of a relapse and/or magnetic resonance imaging activity (new and/or contrast-enhancing lesions) over 24 months of follow-up
  • primary outcome was observed in 94 patients (60.3%) in the vitamin D group and 109 patients (74.1%) in the placebo group (hazard ratio, 0.66)
    • was a statistically significant difference
  • study authors concluded that:
    • oral cholecalciferol 100 000 IU every 2 weeks significantly reduced disease activity in CIS and early relapsing-remitting MS

Reference:

  1. Thouvenot E, Laplaud D, Lebrun-Frenay C, et al. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. JAMA. Published online March 10, 2025

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.